# US 2012/0251523 A1 · Methods of Modulating TGFbeta Signaling

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251523 A1
- Document ID: US20120251523A1
- Status: Published application
- Kind: A1
- Application number: 13/355,798
- Filed: 2012-01-23
- Published: 2012-10-04
- Earliest claimed: 2011-01-24
- Assignees: New York University
- Inventors: Derya Unutmaz; Aimee El Hed
- Web page: https://patentgrep.com/patent/US20120251523A1

## CPC

- G01N 33/56972: {White blood cells}
- A61K 38/4886: {Metalloendopeptidases (3.4.24), e.g. collagenase}
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12Y 304/24046: Adamalysin (3.4.24.46)
- G01N 2333/495: Transforming growth factor [TGF]
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

The present invention provides methods of identifying the presence of or quantifying the amount of one or more of T helper (Th) cells and iTreg cells present in a sample by identifying the presence of an ADAM or the amount of an ADAM, such as ADAM12, present in a sample. The present invention also provides methods for increasing or decreasing signaling of a TGF such as TGFβ by increasing or decreasing the biological activity or expression of an ADAM. Further, the present invention provides methods for inhibiting or stimulating, downregulating or upregulating, an immune response, and for treating diseases associated with an immune response such as cancer, viral, bacterial and fungal infections, autoimmune diseases and graft versus host diseases. Still further, the invention provides screening methods effective for identifying therapeutic agents, pharmaceutical compositions containing therapeutic agents, and vaccines.

## Claims

### Claim 1

A method of identifying the presence of or quantifying the amount of one or more of T helper (Th) cells and iTreg cells present in a sample such as a biological sample comprising identifying the presence of an ADAM or the amount of an ADAM present in the sample.

### Claim 2 (depends on 1)

The method of claim 1 wherein the Th cells are Th17 cells or iTregs.

### Claim 3 (depends on 1)

The method of claim 1 wherein the ADAM is ADAM12.

### Claim 4 (depends on 1)

The method of claim 1 wherein the ADAM is detected or quantified in a sample using an antibody.

### Claim 5

A method for increasing signaling of a TGF comprising increasing the biological activity or expression of an ADAM or administering an ADAM.

### Claim 6 (depends on 5)

The method of claim 5 wherein the TGF is TGFβ.

### Claim 7 (depends on 5)

The method of claim 5 wherein the ADAM is ADAM12.

### Claim 8 (depends on 5)

The method of claim 5 wherein the biological activity or expression of an ADAM is effected by administering an agent that stimulates expression of an ADAM.

### Claim 9 (depends on 8)

The method of claim 8 wherein the agent that stimulates expression of an ADAM is selected from the group consisting of a small molecule, an antibody, a DNA or RNA, or a genetic construct.

### Claim 10

A method for decreasing signaling of a TGF comprising decreasing the biological activity or expression of an ADAM or administering an agent that functions to inhibit the expression or biological activity of an ADAM.

### Claim 11 (depends on 10)

The method of claim 10 wherein the TGF is TGFβ.

### Claim 12 (depends on 10)

The method of claim 10 wherein the ADAM is ADAM12.

### Claim 13 (depends on 10)

The method of claim 10 wherein the agent that functions to inhibit the expression or biological activity of an ADAM is selected from the group consisting of a small molecule, an antibody, and an interfering RNA or DNA molecule.

### Claim 14

A method for inhibiting an immune response comprising increasing the biological activity or expression of an ADAM or administering an ADAM.

### Claim 15 (depends on 14)

The method of claim 14 wherein the ADAM is ADAM12.

### Claim 16 (depends on 14)

The method of claim 14 wherein the biological activity or expression of an ADAM is effected by administering an agent that stimulates expression of an ADAM.

### Claim 17 (depends on 16)

The method of claim 16 wherein the agent that stimulates expression of an ADAM is selected from the group consisting of a small molecule, an antibody, a DNA or RNA, or a genetic construct.

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37

(canceled)
